Introduction
A large amount of research has been performed in search of factors predicting treatment outcomes in heart failure patients receiving cardiac resynchronisation therapy (CRT) [
1], but the role of patient-reported factors has largely been neglected [
2]. A recent meta-analysis showed that disease-specific health status assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ) or Minnesota Living with Heart Failure Questionnaire (MLHFQ) is a predictor of prognosis in heart failure patients, above and beyond traditional risk factors [
3]. The PROSPECT (Predictors of Response to CRT) trial found that a five-point improvement on the KCCQ in the first 6 months of CRT was associated with a 15 % lower risk of all-cause mortality during 18 months of follow-up [
4]. In accordance, a sub-study of the TRUST-CRT (Triple-Site versus Standard CRT) study showed that unimproved scores on the MLHFQ in the first 6 months of CRT decreased the probability of event-free survival by 2.2 times, independent of clinical and echocardiographic response [
5]. In order to enhance risk stratification of heart failure patients indicated for CRT, it is important to know the prognostic value of patient-reported health status assessed prior to implantation.
The aim of the current study was to examine whether pre-implantation heart failure-specific health status is associated with (1) a combined endpoint of first-time cardiac-related hospital admission or all-cause death, (2) the total number of cardiac-related hospital admissions, and (3) the cumulative length of cardiac-related hospital stays, during a follow-up of 4 years after CRT implantation, independent of sociodemographic, clinical and psychological risk factors.
Discussion
This study examined the value of pre-implantation patient-reported health status in predicting four-year morbidity and mortality in patients treated with CRT. Results showed that poor heart failure-specific health status (i.e., KCCQ summary score < 50) prior to implantation was independently associated with a 2.5-fold increased risk of first-time cardiac-related hospital admission or all-cause death after CRT implantation. Looking at cardiac-related hospital admissions, health status was not significantly associated with the absolute number of admissions, but with the total number of days spent in hospital during follow-up. On average, patients with a low pre-implantation KCCQ score spent 8.7 days in hospital due to cardiac reasons, compared with 3.4 days for patients reporting a good health status.
The current results underline that the routine assessment of patient-reported health status is essential for clinical evaluation and risk stratification of heart failure patients [
18,
19]. Measures such as the KCCQ add valuable information to what is routinely obtained during clinic visits, as they are only marginally associated with traditional measures of heart failure severity and treatment response, including physician-rated NYHA class [
6,
20,
21]. The NYHA classification system has been criticised due to the method not being standardised making it poorly reproducible with high inter-rater variation, especially when differentiating patients belonging to class II versus III [
22]. The KCCQ on the other hand has a clear cut-off point with a summary score of < 50 indicating poor health status, which was demonstrated to be independently associated with a 1.5–2 point increased risk of morbidity and mortality in a broad range of heart failure patients [
3], now including those receiving CRT. Regarding serial health status assessments, a mean change of ≥ 5 points in the KCCQ summary score has been associated with a 9 % change in the adjusted HR for death in ischaemic heart failure patients [
23], and 15 % in CRT patients [
4]. It could be hypothesised that patients reporting a poor KCCQ score prior to implantation, which does not improve during the first months of CRT, have the worst prognosis; this should be investigated in future studies.
Besides poor health status, male sex was independently associated with a higher risk of hospitalisation or death. This finding confirms a recent meta-analysis showing that women obtain greater reduction in risk of death, hospitalisation for heart failure and ventricular arrhythmias with CRT than men [
24]. There was no independent association between sex and the total length of hospital stays, but we did find that patients with a QRS duration of > 150 ms spend less days in hospital. Accordingly, a meta-analysis of six randomised clinical trials has demonstrated that the benefit of CRT appears to be most profound in patients with a pre-implantation QRS duration wider than 150 ms [
25]. Looking at sociodemographic factors, having a partner and being employed were associated with a reduced number of admitted days. Previous studies in heart failure patients also found a correlation between partner status and risk of readmission and suggested that the lack of a social support system at home might condemn patients to be admitted sooner and longer [
26]. In addition, the current and previous results from a study in ischaemic heart disease patients showed that being employed is independently associated with a shorter total length of hospital stay during follow-up [
16]. An explanation for this association might be that employed patients are concerned about missing work due to illness, making them wait longer before going to the hospital [
27]. Finally, we found that an unhealthy lifestyle was associated with a lower incidence rate of days in hospital. Post-hoc analysis showed that, surprisingly, smoking at the time of implantation drove this association. As we do not have data regarding smoking status in the years prior to implantation or smoking cessation during follow-up, this finding is difficult to interpret. More research is needed to gain a better understanding of the determinants of mortality and morbidity in CRT patients in order to optimise response rates.
Patient-reported health status is increasingly being recognised as an essential part of patient-centred care, yet its incorporation in cardiovascular research and practice is far from standard [
18]. Although instruments such as the KCCQ are low-cost, easy to administer and highly interpretable with clear cut-off values, the most challenging part remains convincing the healthcare providers of their applicability and usefulness [
28]. In 2014, the European Society of Cardiology published recommendations to advance the use of patient-reported outcomes in cardiovascular medicine, including training of physicians to use these measures in clinical decision-making [
29], particularly for therapies associated with trade-offs between improved quality of life and prolonged survival [
30]. Once patients with poor health status are identified, they should be offered appropriate interventions in order to improve their quality of life and prognosis. Aerobic exercise training and/or cognitive behavioural therapy have been shown to improve outcomes in heart failure and implantable cardioverter defibrillator patients [
31‐
34]. But the number of studies is small and they suffer from methodological limitations [
33,
34]. Large-scale intervention trials are warranted to increase our knowledge on how and when to offer behavioural intervention programmes in cardiac practice.
The major limitation of this study is it being a single-centre study with a relatively small sample size and low number of events. However, strengths of this study comprise the follow-up period of 4 years, the use of a heart failure-specific health status measure and the adjustment for clinical, as well as sociodemographic and psychological characteristics.
In conclusion, the current study adds to the literature advocating routine use of instruments such as the KCCQ, which provide a quick and highly interpretable assessment of patient-perceived symptoms of heart failure, functional limitations and quality of life. They capture what is important to patients and provide simple and significant indicators of prognosis and outcomes of heart failure treatments such as CRT, above and beyond traditional risk factors.
Acknowledgements
We would like to thank Corline Brouwers, Margot Bogaard, Mirjam Mastenbroek, Iris ter Horst and Jetske van ’t Sant for their help with the recruitment of patients or collection of clinical data.